FDA approves antifungal drug for weakened immune systems

09/18/2006 | Wall Street Journal, The

The agency says it approved Schering-Plough's Noxafil, which is designed to prevent fungal infections caused by certain molds and yeast-like fungus. The FDA specifically cited the drug's use for patients whose immune systems have been debilitated after bone-marrow transplants and those whose white blood cell counts fall following cancer chemotherapy.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC